Comparison the Effect of Arbidol Plus Hydroxychloroquine vs Hydroxychloroquine Alone in Treatment of COVID-19 Disease: A Randomized Clinical Trial

Author(s): Rozita Khodashahi, Hamidreza Naderi, Amin Bojdy, Ali Akbar Heydari, Ashraf Tavanaee Sani, Mohammad Javad Ghabouli, Mohammad Reza Sarvghad, Mahboubeh Haddad, Mahnaz Arian, Shahrzad Jahanian, Saeedeh Mazidi, Maziar Mortazavi Pasand, Binyamin Hoseini, Maliheh Dadgarmoghaddam, Ali Khorsand, Mandana Khodashahi*

Journal Name: Current Respiratory Medicine Reviews

Volume 16 , Issue 4 , 2020

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Background and Aim: The main challenging issue about coronavirus disease 2019 (COVID-19) is the production of safe and stable vaccines, which is a very long process. Due to the emergency situation, regular and extensive screening of available and traditional drugs, which are commonly used for the treatment of similar viral diseases, can be a reasonable option. The present study aimed to compare the administration of hydroxychloroquine (HCQ) plus arbidol to the use of HCQ alone in the treatment of COVID-19 infection.

Methods and Materials: This single-blind randomized controlled trial was carried out on a total of 100 patients with COVID-19 referring to the infection ward of Imam Reza Hospital in Mashhad, Iran, in 2020. The patients were randomly assigned to two HCQ alone and HCQ plus arbidol groups.

Results: According to the obtained results, hematological parameters, including white blood cell count, hemoglobin level, lymphocyte count, and platelet count, improved in patients with COVID-19 after the treatment with both HCQ plus arbidol and HCQ alone (P<0.005). The mean values of the reduction time of C-reactive protein (CRP) were 4.48±1.24 and 8.22±2.08 days in the arbidol and HCQ alone groups, respectively, indicating that CRP decreased faster in the arbidol group than that reported for the HCQ alone group (Z=0.-7.85; P<0.000). The mean scores of hospital stay were reported as 5.89±2.04 and 9.35±3.72 days in the arbidol and HCQ alone groups, respectively (Z=-4.31; P<0.005). All the patients in the arbidol group survived, while 6% of the subjects in the HCQ alone group died. In addition, the drug regimen was not changed for any patient, and no subject was transferred to the intensive care unit in the arbidol group.

Conclusion: In summary, the administration of both arbidol and HCQ leads to the improvement of the hematological parameters. The present study introduced arbidol as an effective treatment for moderate to severe patients with COVID-19, which not only reduced the time of CRP normalization level but also decreased the hospitalization duration and mortality compared to those reported for HCQ.

Keywords: COVID-19, hydroxychloroquine, arbidol, umifenovir, viral diseases, emergency situation.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2020
Published on: 01 March, 2021
Page: [252 - 262]
Pages: 11
DOI: 10.2174/1573398X17666210129125703
Price: $65

Article Metrics

PDF: 17